News | Radiation Therapy | September 11, 2019

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

Beta Testing begins of RadCalc 3Dmc version 7.1.1.0 utilizing Monte Carlo 3D dose volume QA technology

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

September 11, 2019 — RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing team. The Monte Carlo 3D module utilizes technology acquired from the McGill University inventors. This release of RadCalc 3Dmc is the second of three 3D Dose Volume second check quality assurance (QA) packages. The completion of the beta test is anticipated in four weeks. An announcement of the final release date will be provided when available for purchase.

RadCalc 3Dmc utilizes the BeamNRC-based Monte Carlo dose calculation engine, providing independent, fast, easy and accurate 3-D dose volume verification for most commonly used treatment planning systems. The RadCalc 3Dmc beta release is compatible with Varian and Elekta machines. Support for additional radiotherapy treatment machines will be available in the near future.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases involving highly heterogeneous structures are analyzed with the highest accuracy and confidence. Flexible implementation options allow users to combine the uncompromised accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs.

RadCalc 3Dmc includes RadCalc AIR (Automated Import & Report) providing a fully automated process with percent difference, dose volume histogram (DVH), Gamma, and Distance to Agreement analysis tools. RadCalc 3Dmc’s fully automated process immediately alerts users to plans that fail to pass pre-set criteria.

RadCalc 3Dmc automatically checks whether DVH objectives are met for critical structures using both the treatment planning system (TPS) and RadCalc 3Dmc dose. Any number of DVH protocols can be loaded and be compared to one another from one analysis screen within RadCalc 3Dmc. Analysis reports are automatically attached to a verified plan and sent to a workstation via email or to a directory of choice on the server.

RadCalc 3Dmc is not yet available for sale in the United States. 

For more information: www.lap-laser.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost